Endo’s $10 million opioid deal with two Ohio counties Tuesday may have appeared small in scope to some, but could the bellwether agreement spell a sigh of relief for the industry on the whole? Investors and analysts seem to think so.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,